<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="523">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100058</url>
  </required_header>
  <id_info>
    <org_study_id>CLIK066B2201</org_study_id>
    <secondary_id>2016-002868-14</secondary_id>
    <nct_id>NCT03100058</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults</brief_title>
  <official_title>A Randomized, Double-blind, Dose-finding Study to Evaluate the Change in Weight After 24 Weeks Treatment With 8 Doses of LIK066 Compared to Placebo in Obese or Overweight Adults, Followed by 24 Weeks Treatment With 2 Doses of LIK066 and Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose-finding study to evaluate the change in weight after 24 weeks treatment with
      8 different doses of LIK066 compared to placebo in obese or overweight adults, followed by
      24 weeks treatment with 2 doses of LIK066 and placebo.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 17, 2017</start_date>
  <completion_date type="Anticipated">August 27, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 27, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in body weight at 24 weeks</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>Dose-response relationship of two dose regimens of LIK066 as measured by the percent change from baseline in body weight relative to placebo after 24 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with response rate according to percent decrease in body weight</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>Responder rates according to percent decrease in body weight either ≥ 5 % or ≥ 10 % from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with response rate according to percent decrease in body weight by subgroup</measure>
    <time_frame>baseline, week 24</time_frame>
    <description>Dose-response relationship for weight loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on waist circumference</measure>
    <time_frame>baseline, week 24, week 48</time_frame>
    <description>Waist circumference will be measured to the nearest 0.1cm in a standing position, at the end of a normal expiration, using a tape at the level of the iliac crest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glycated hemoglobin A1c (HbA1c)</measure>
    <time_frame>baseline, week 24, week 48</time_frame>
    <description>HbA1c will be measured from a blood sample obtained at indicated visits and will be analyzed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose (FPG)</measure>
    <time_frame>baseline, week 24, week 48</time_frame>
    <description>FPG will be measured from a blood sample obtained after an overnight fast (at least 8h after last evening food intake).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean sitting systolic blood pressure (msSBP) and mean sitting diastolic blood pressure (msDBP)</measure>
    <time_frame>baseline, Week 24, Week 48</time_frame>
    <description>At each study visit (baseline, week 24, Week 48), after the subject has been sitting for 5 minutes with the back supported and both feet placed on the floor, SBP and DBP will be measured three times using the automatic BP monitor and an appropriate size cuff. All 3 sitting BP readings will be used for evaluation of mean sitting SBP and DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 24-hour urinary glucose excretion</measure>
    <time_frame>baseline, week 24, week 48</time_frame>
    <description>Urinary glucose excretion will be measured from 24-hour urinary collection at indicated visits and will be analyzed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight in the overall population and by subgroups</measure>
    <time_frame>baseline, week 24, week 48</time_frame>
    <description>Change in weight from baseline to week 24 and 48 in the overall population and by subgroups will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour urinary calcium and phosphorus excretion</measure>
    <time_frame>week 24, week 48</time_frame>
    <description>24-hour urinary calcium and phosphorus excretion (mg/dL) will be reported in this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LIK066: Area under the plasma concentration-time curve from time zero time 't' (AUC0-t)</measure>
    <time_frame>Baseline, 0 hour (pre-dose) and approximately 1 hour, 2 hours, 4 hours and 6 hours post dose on week 12, 24 and 34</time_frame>
    <description>Area under the plasma concentration-time curve from time zero time 't' where t is a defined time point after administration (AUC0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LIK066: Observe maximum plasma concentration (cmax)</measure>
    <time_frame>Baseline, 0 hour (pre-dose) and approximately 1 hour, 2 hours, 4 hours and 6 hours post dose on week 12, 24 and 34</time_frame>
    <description>Observe maximum plasma concentration following administration of LIK066 (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LIK066: Time to reach the maximum concentration (Tmax)</measure>
    <time_frame>Baseline, 0 hour (pre-dose) and approximately 1 hour, 2 hours, 4 hours and 6 hours post dose on week 12, 24 and 34</time_frame>
    <description>Time to reach the maximum concentration after administration of LIK066 (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LIK066: Last non-zero concentration area under the curve (AUClast)</measure>
    <time_frame>Baseline, 0 hour (pre-dose) and approximately 1 hour, 2 hours, 4 hours and 6 hours post dose on week 12, 24 and 34</time_frame>
    <description>Last non-zero concentration area under the curve (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting lipid profile (triglycerides/cholesterol)</measure>
    <time_frame>baseline, week 24, week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting lipid profile (lipoproteins)</measure>
    <time_frame>baseline, week 24, week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in High sensitive C-reactive protein (hsCRP)</measure>
    <time_frame>baseline, week 24, week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">432</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>LIK066</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects eligible for randomization will be assigned to different dosing groups which are defined by once daily or twice daily dosing frequency for 24 weeks. Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>subjects randomized to this treatment arm will receive LIK066 matching placebo tablets for 24 weeks. From week 24 to week 48, half of the patients who received placebo in the first 24 weeks will receive Dose A LIK066 once daily and other half will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LIK066</intervention_name>
    <description>LIK066 will be supplied in different doses as tablets to be taken orally.</description>
    <arm_group_label>LIK066</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. informed consent

          2. (BMI&gt;=30) or (BMI&gt;=27 with history of CV disease, hypertension, dyslipidemia,
             pre-diabetes or type 2 diabetes mellitus, sleep-apnea syndrome)

          3. willing to comply with life-style intervention and treatment during the full duration
             of the study (approximately 54 weeks)

        Exclusion Criteria:

          -  Hypersensitivity to any of the study medications

          -  Pregnancy or lactating women

          -  History of malignancies

          -  Use of pharmacologically active weight loss products

          -  Bariatric surgery

          -  Ketoacidosis, lactic acidosis, hyperosmolar coma in the 6 months before the screening
             visit.

          -  HbA1c &gt;10% at the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>March 3, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Overweight</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
